title: Readministration of EGFR tyrosine kinase inhibitor in non-small cell lung cancer patients after initial failure, what affects its efficacy?
abstract: Few therapeutic options are available for non-small cell lung cancer (NSCLC) after failure to primary epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Since TKI rechallenge is one of the most common salvage approaches in clinical practice, we sought to identify the independent factors that associated with 2(nd) progression progression-free survival (PFS) and overall survival (OS). Seventy-two consecutive EGFR-mutated NSCLC patients with TKI retreatment after initial failure were retrospectively analyzed in this study. Univariate survival analysis and Cox proportional hazards regression model was used to determine if EGFR-TKIs readministration is tolerable as well as efficacious for a certain group of patients.
authors.affiliation: 1] State Key Laboratory of Oncology in Southern China, and Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China [2] Lung Cancer Research Center, Sun Yat-Sen University, Guangzhou, China [3].
authors.forename: Ze-Rui
authors.initials: ZR
authors.lastname: Zhao
authors.affiliation: 1] State Key Laboratory of Oncology in Southern China, and Department of Anesthesia, Sun Yat-Sen University Cancer Center, Guangzhou, China [2].
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.affiliation: 1] State Key Laboratory of Oncology in Southern China, and Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China [2] Lung Cancer Research Center, Sun Yat-Sen University, Guangzhou, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Long
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009154:Mutation; D016016:Proportional Hazards Models; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012189:Retrospective Studies; D016879:Salvage Therapy; D016019:Survival Analysis
chemical_list: D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors
references.citation: Lung Cancer. 2011 Nov;74(2):268-73
references.pmid: 21529987
references.citation: Lung Cancer. 2012 Jul;77(1):121-7
references.pmid: 22333554
references.citation: J Clin Oncol. 2010 Jan 10;28(2):357-60
references.pmid: 19949011
references.citation: Lung Cancer. 2010 Apr;68(1):99-104
references.pmid: 19540616
references.citation: Clin Lung Cancer. 2012 Nov;13(6):458-63
references.pmid: 22402083
references.citation: BMC Cancer. 2011 Jan 01;11:1
references.pmid: 21194487
references.citation: N Engl J Med. 2011 Mar 10;364(10):947-55
references.pmid: 21388312
references.citation: Chin J Cancer. 2012 Oct;31(10):491-9
references.pmid: 22572014
references.citation: Oncology. 2010;79(5-6):423-9
references.pmid: 21474967
references.citation: Lung Cancer. 2013 Jan;79(1):33-9
references.pmid: 23079155
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Cancer. 2013 Dec 15;119(24):4325-32
references.pmid: 24105277
references.citation: Eur Respir J. 2007 Jan;29(1):128-33
references.pmid: 17005582
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: J Clin Oncol. 2013 Mar 10;31(8):1070-80
references.pmid: 23401451
references.citation: Clin Cancer Res. 2012 Feb 15;18(4):938-44
references.pmid: 22167408
references.citation: Lancet Oncol. 2011 Aug;12(8):735-42
references.pmid: 21783417
references.citation: Cancer Res. 2008 Nov 15;68(22):9479-87
references.pmid: 19010923
references.citation: Lancet Oncol. 2012 Mar;13(3):239-46
references.pmid: 22285168